Recurrence biomarkers of triple negative breast cancer treated with neoadjuvant chemotherapy and anti-EGFR antibodies.
Journal
NPJ breast cancer
ISSN: 2374-4677
Titre abrégé: NPJ Breast Cancer
Pays: United States
ID NLM: 101674891
Informations de publication
Date de publication:
17 Sep 2021
17 Sep 2021
Historique:
received:
24
01
2021
accepted:
20
08
2021
entrez:
18
9
2021
pubmed:
19
9
2021
medline:
19
9
2021
Statut:
epublish
Résumé
To find metastatic recurrence biomarkers of triple-negative breast cancer (TNBC) treated by neoadjuvant chemotherapy and anti-EGFR antibodies (NAT), we evaluated tumor genomic, transcriptomic, and immune features, using MSK-IMPACT assay, gene arrays, Nanostring technology, and TIL assessment on H&E. Six patients experienced a rapid fatal recurrence (RR) and other 6 had later non-fatal recurrences (LR). Before NAT, RR had low expression of 6 MHC class I and 13 MHC class II genes but were enriched in upregulated genes involved in the cell cycle-related pathways. Their TIL number before NAT in RR was very low (<5%) and did not increase after treatment. In post-NAT residual tumors, RR cases showed high expression of SOX2 and CXCR4. Our results indicate that high expression of cell cycle genes, combined with cold immunological phenotype, may predict strong TNBC resistance to NAT and rapid progression after it. This biomarker combination is worth validation in larger studies.
Identifiants
pubmed: 34535679
doi: 10.1038/s41523-021-00334-5
pii: 10.1038/s41523-021-00334-5
pmc: PMC8448841
doi:
Types de publication
Journal Article
Langues
eng
Pagination
124Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Informations de copyright
© 2021. The Author(s).
Références
Nat Biotechnol. 2013 Mar;31(3):213-9
pubmed: 23396013
Semin Cancer Biol. 2018 Oct;52(Pt 2):16-25
pubmed: 29024776
Clin Cancer Res. 2013 May 15;19(10):2723-33
pubmed: 23549873
Bioinformatics. 2012 Jun 1;28(11):1546-8
pubmed: 22513995
Cancer Res. 2019 Jul 1;79(13):3466-3478
pubmed: 31048497
Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4429-34
pubmed: 17671126
Nucleic Acids Res. 2016 Jan 4;44(D1):D481-7
pubmed: 26656494
Genome Biol. 2015 May 22;16:107
pubmed: 25994018
J Clin Oncol. 2010 Jul 10;28(20):3271-7
pubmed: 20498394
Lancet Oncol. 2018 Jan;19(1):40-50
pubmed: 29233559
Front Pharmacol. 2018 Aug 21;9:942
pubmed: 30186173
Ann Oncol. 2015 Feb;26(2):259-71
pubmed: 25214542
Sci Rep. 2017 Apr 07;7:45828
pubmed: 28387221
Cancer Inform. 2012;11:147-56
pubmed: 22872785
Nucleic Acids Res. 2016 Sep 19;44(16):e131
pubmed: 27270079
Bioinformatics. 2009 Jul 15;25(14):1754-60
pubmed: 19451168
Nat Methods. 2014 Oct;11(10):1033-6
pubmed: 25128977
J Immunother Cancer. 2018 Jun 22;6(1):63
pubmed: 29929551
Genome Biol. 2014 Oct 28;15(10):484
pubmed: 25348012
Proc Natl Acad Sci U S A. 2017 Aug 22;114(34):E7159-E7168
pubmed: 28784776
Cancers (Basel). 2018 Sep 04;10(9):
pubmed: 30181502
Int J Cancer. 2016 May 1;138(9):2274-80
pubmed: 26649807
Am J Pathol. 2017 Oct;187(10):2139-2151
pubmed: 28736315
Ann Oncol. 2014 Aug;25(8):1570-7
pubmed: 24827135
Sci Transl Med. 2017 Jul 5;9(397):
pubmed: 28679654
Future Oncol. 2017 Apr;13(9):843-857
pubmed: 28075166
Ann Oncol. 2014 Mar;25(3):611-618
pubmed: 24401929
Nat Biotechnol. 2012 May;30(5):413-21
pubmed: 22544022
Nat Biotechnol. 2016 Feb;34(2):155-63
pubmed: 26619011
Clin Cancer Res. 2020 Nov 1;26(21):5668-5681
pubmed: 32826327
OMICS. 2012 May;16(5):284-7
pubmed: 22455463
Genome Res. 2010 Sep;20(9):1297-303
pubmed: 20644199
Cell. 2015 Jan 15;160(1-2):48-61
pubmed: 25594174
J Clin Oncol. 2010 Apr 10;28(11):1821-8
pubmed: 20231683
Nat Rev Clin Oncol. 2016 Nov;13(11):674-690
pubmed: 27184417
PLoS One. 2016 Jun 16;11(6):e0157368
pubmed: 27310713
Clin Cancer Res. 2015 Apr 1;21(7):1688-98
pubmed: 25208879
EBioMedicine. 2019 Apr;42:352-362
pubmed: 30846393
Nucleic Acids Res. 2015 Apr 20;43(7):e47
pubmed: 25605792
Nucleic Acids Res. 2015 Jan;43(Database issue):D1049-56
pubmed: 25428369
Oncoimmunology. 2017 Mar 16;6(5):e1305531
pubmed: 28638726
J Clin Oncol. 2007 Oct 1;25(28):4414-22
pubmed: 17785706
PLoS One. 2013 Dec 11;8(12):e82125
pubmed: 24349199
Commun Biol. 2018 Mar 22;1:20
pubmed: 30271907
Nature. 2012 Apr 04;486(7403):395-9
pubmed: 22495314
Proc Natl Acad Sci U S A. 2018 Feb 6;115(6):E1239-E1248
pubmed: 29367423
Curr Opin Immunol. 2018 Apr;51:123-132
pubmed: 29567511
Breast Cancer Res. 2013;15(5):R103
pubmed: 24172169
J Natl Cancer Inst. 2018 Sep 1;110(9):1030-1034
pubmed: 29506079
Lancet. 2014 Jul 12;384(9938):164-72
pubmed: 24529560
Clin Cancer Res. 2016 Mar 15;22(6):1499-509
pubmed: 26515496
Genome Biol. 2013 Apr 29;14(4):R34
pubmed: 23618380
Cancer Discov. 2014 Feb;4(2):232-45
pubmed: 24356096
Genome Res. 2012 Mar;22(3):568-76
pubmed: 22300766
BMC Cancer. 2014 Jan 29;14:49
pubmed: 24475985
J Pathol Transl Med. 2019 Mar;53(2):75-85
pubmed: 30424591
Bioinformatics. 2012 Jul 15;28(14):1811-7
pubmed: 22581179
Mol Biosyst. 2016 Feb;12(2):477-9
pubmed: 26661513
BMC Cancer. 2011 Oct 20;11:454
pubmed: 22014037
Oncologist. 2012;17(11):1394-401
pubmed: 22941971
Ann Oncol. 2019 Feb 1;30(2):236-242
pubmed: 30590484
Cell. 2013 Feb 14;152(4):714-26
pubmed: 23415222
Int Immunopharmacol. 2020 Oct;87:106797
pubmed: 32702599
Front Immunol. 2019 Dec 18;10:2802
pubmed: 31921107
J Clin Invest. 2011 Jul;121(7):2750-67
pubmed: 21633166
Clin Cancer Res. 2013 Oct 1;19(19):5533-40
pubmed: 23948975
Cancer Sci. 2017 Jul;108(7):1520-1529
pubmed: 28474753